MA29540B1 - Comprime drageifie - Google Patents

Comprime drageifie

Info

Publication number
MA29540B1
MA29540B1 MA30465A MA30465A MA29540B1 MA 29540 B1 MA29540 B1 MA 29540B1 MA 30465 A MA30465 A MA 30465A MA 30465 A MA30465 A MA 30465A MA 29540 B1 MA29540 B1 MA 29540B1
Authority
MA
Morocco
Prior art keywords
coating
drageified
compressor
active ingredient
stabilized
Prior art date
Application number
MA30465A
Other languages
English (en)
Inventor
Yoshihiro Uchiyama
Yoshinori Nakano
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37498554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29540(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA29540B1 publication Critical patent/MA29540B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

L'INVENTION CONCERNE UNE PRÉPARATION PHARMACEUTIQUE DANS LAQUELLE UN PRINCIPE ACTIF INSTABLE EN PRÉSENCE D'OXYGÈNE EST STABILISÉ EN ENROBANT UNE PORTION CONTENANT LEDIT PRINCIPE ACTIF AVEC UNE COUCHE D¿ENROBAGE EN SUCRE CONTENANT (1) UN ALCOOL GLUCIDIQUE EN TANT QUE BASE D'ENROBAGE ET (2) UN LIANT.
MA30465A 2005-06-10 2007-12-10 Comprime drageifie MA29540B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005171443 2005-06-10

Publications (1)

Publication Number Publication Date
MA29540B1 true MA29540B1 (fr) 2008-06-02

Family

ID=37498554

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30465A MA29540B1 (fr) 2005-06-10 2007-12-10 Comprime drageifie

Country Status (19)

Country Link
US (1) US20090030064A1 (fr)
EP (1) EP1889611A1 (fr)
JP (1) JPWO2006132360A1 (fr)
KR (1) KR20080014014A (fr)
CN (1) CN101193625A (fr)
AR (1) AR054133A1 (fr)
AU (1) AU2006256038A1 (fr)
BR (1) BRPI0611058A2 (fr)
CA (1) CA2610342A1 (fr)
CR (1) CR9523A (fr)
IL (1) IL187407A0 (fr)
MA (1) MA29540B1 (fr)
NO (1) NO20080175L (fr)
NZ (1) NZ563820A (fr)
PE (1) PE20070077A1 (fr)
RU (1) RU2407515C2 (fr)
TW (1) TW200716207A (fr)
WO (1) WO2006132360A1 (fr)
ZA (1) ZA200710333B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009101940A1 (fr) * 2008-02-11 2009-08-20 Dainippon Sumitomo Pharma Co., Ltd. Comprimé présentant des propriétés d'élution améliorées
TW201021832A (en) * 2008-09-30 2010-06-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
ES2656853T3 (es) * 2009-09-02 2018-02-28 Nippon Soda Co., Ltd. Agente de recubrimiento que comprende hidroxialquilcelulosa
CN101804042A (zh) * 2010-04-16 2010-08-18 山东新华制药股份有限公司 普拉格雷片剂的制备方法
WO2014203029A1 (fr) * 2013-06-17 2014-12-24 Freescale Semiconductor, Inc. Programmation efficace dans un système asynchrone basé sur la résolution de conflits
FR3013186B1 (fr) * 2013-11-19 2019-07-19 Roquette Freres Nouveaux snacks non allergenes contenant des proteines vegetales
CN103977427A (zh) * 2014-05-08 2014-08-13 王�琦 一种糖衣产气粉配方及其制备方法
FR3067567B1 (fr) * 2017-06-19 2019-07-05 Roquette Freres Nouveau procede de drageification et formes solides drageifiees presentant des formes irregulieres

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0126661B2 (fr) * 1979-10-17 1989-05-24 Roquette Freres
JPH0816052B2 (ja) * 1988-11-21 1996-02-21 エスエス製薬株式会社 糖衣錠
JP3507211B2 (ja) * 1995-07-13 2004-03-15 三菱化学株式会社 糖衣液及び糖衣錠
ES2213407T3 (es) * 1998-12-04 2004-08-16 Takeda Chemical Industries, Ltd. Derivados de benzofurano, procedimiento para su preparacion, y sus usos.
JP2001139495A (ja) * 1999-11-19 2001-05-22 Shin Etsu Chem Co Ltd フィルムコーティング剤及び経口固形製剤
AT500063A1 (de) * 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
JP2002047174A (ja) * 2000-05-26 2002-02-12 Towa Chem Ind Co Ltd 無糖コーティング製剤及びその製造方法
JP2002179559A (ja) * 2000-10-06 2002-06-26 Takeda Chem Ind Ltd 薄層糖衣錠およびその製造方法
JP2003113060A (ja) * 2001-10-02 2003-04-18 Lion Corp 発泡成分含有糖衣物
JP4336074B2 (ja) * 2001-11-15 2009-09-30 三菱商事フードテック株式会社 色調および食感が良好な硬質糖衣錠剤
WO2003051355A1 (fr) * 2001-12-19 2003-06-26 Takeda Chemical Industries, Ltd. Compositions solides refermant des composes instables a l'oxygene et procede de stabilisation de ces composes
JP4590034B2 (ja) * 2002-01-31 2010-12-01 三菱商事フードテック株式会社 硬質糖衣製剤、糖衣液及び硬質糖衣製剤の製造方法
JP2004123578A (ja) * 2002-09-30 2004-04-22 Dainippon Ink & Chem Inc 糖衣錠およびその製造方法
JP2005298373A (ja) * 2004-04-08 2005-10-27 Kyowa Hakko Kogyo Co Ltd 吸水性アミノ酸含有糖衣錠剤
JP4984455B2 (ja) * 2004-08-18 2012-07-25 日本新薬株式会社 二重被覆錠剤

Also Published As

Publication number Publication date
NZ563820A (en) 2010-03-26
AU2006256038A1 (en) 2006-12-14
RU2007145426A (ru) 2009-06-20
PE20070077A1 (es) 2007-02-07
AR054133A1 (es) 2007-06-06
CR9523A (es) 2008-02-04
EP1889611A1 (fr) 2008-02-20
WO2006132360A1 (fr) 2006-12-14
US20090030064A1 (en) 2009-01-29
NO20080175L (no) 2008-03-04
BRPI0611058A2 (pt) 2011-02-22
RU2407515C2 (ru) 2010-12-27
IL187407A0 (en) 2008-02-09
JPWO2006132360A1 (ja) 2009-01-08
TW200716207A (en) 2007-05-01
ZA200710333B (en) 2009-03-25
CN101193625A (zh) 2008-06-04
CA2610342A1 (fr) 2006-12-14
KR20080014014A (ko) 2008-02-13

Similar Documents

Publication Publication Date Title
MA29540B1 (fr) Comprime drageifie
Price et al. Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice
Garibov et al. Synthesis of 4, 5-disubstituted-2-thioxo-1, 2, 3, 4-tetrahydropyrimidines and investigation of their acetylcholinesterase, butyrylcholinesterase, carbonic anhydrase I/II inhibitory and antioxidant activities
Benhar et al. Protein denitrosylation: enzymatic mechanisms and cellular functions
Bae et al. Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol‐induced oxidative injury in mouse liver
López-Lluch et al. Mitochondrial responsibility in ageing process: innocent, suspect or guilty
Maurer et al. Inhibitors of the NAD+-dependent protein desuccinylase and demalonylase Sirt5
MA35430B1 (fr) Procédés de réduction du taux de lipoprotéine(a) par l'administration d'un inhibiteur de proprotéine convertase subtilisine/kexine-9 (pcsk9)
Chen et al. Evaluation of gender-related differences in various oxidative stress enzymes in mice
Wenzel et al. Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH‐2−/− mice
Wang et al. Protective effect of Lysimachia christinae against acute alcoholinduced liver injury in mice
Jiménez de Oya et al. Targeting host metabolism by inhibition of acetyl-Coenzyme A carboxylase reduces flavivirus infection in mouse models
Tai et al. Endogenous molecules stimulating N-acylethanolamine-hydrolyzing acid amidase (NAAA)
PE20011223A1 (es) Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico
Kojanian et al. Statins prevent dextrose-induced endoplasmic reticulum stress and oxidative stress in endothelial and HepG2 cells
Paino et al. Effect of therapeutic plasma concentrations of non-steroidal anti-inflammatory drugs on the production of reactive oxygen species by activated rat neutrophils
Wong-Baeza et al. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease
ATE388143T1 (de) Cumarin derivate und ihre verwendung als anticoagulantien
Staub et al. Mechanism for benomyl action as a mitochondrial aldehyde dehydrogenase inhibitor in mice
Tasdemir Type II fatty acid biosynthesis, a new approach in antimalarial natural product discovery
Sugiura et al. N-arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues
Siemieniuk et al. Oxidative modifications of rat liver cell components during Fasciola hepatica infection
KR101401253B1 (ko) Ｐｃｓｋ9 발현 억제를 통한 저밀도지단백 수용체 증가 유도용 조성물
Lu et al. Enantioselective apoptosis and oxidative damage induced by individual isomers of profenofos in primary hippocampal neurons
Rabêlo et al. Redox unbalance: NADPH oxidase as therapeutic target in blood pressure control